How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006–2014)

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 1134-1145

  Schaffer, Andrea L ^a   Pearson, Sallie Anne ^a   Buckley, Nicholas A ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Australia; fixed dose combinations; hypertension; pharmacoepidemiology

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA SECRETASE INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUSTRALIAN; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84986256916     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13043     Document Type: Article

References (38)

1. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009; 27: 963–75.
2. Furmaga EM, Cunningham FE, Cushman WC, Dong D, Jiang R, Basile J, et al. National utilization of antihypertensive medications from 2000 to 2006 in the Veterans Health Administration: focus on thiazide diuretics. J Clin Hypertens (Greenwich) 2008; 10: 770–8.
3. Cheung BM, Wong YL, Lau CP. Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the hypertension clinic 1996–2004. Br J Clin Pharmacol 2005; 60: 90–7.
4. Vincze G, Barner JC, Bohman T, Linn WD, Wilson JP, Johnsrud MT, et al. Use of antihypertensive medications among United States veterans newly diagnosed with hypertension. Curr Med Res Opin 2008; 24: 795–805.
5. Kaiser EA, Lotze U, Schafer HH. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? Clin Interv Aging 2014; 9: 459–75.
6. Evans CD, Eurich DT, Remillard AJ, Shevchuk YM, Blackburn D. First-fill medication discontinuations and nonadherence to antihypertensive therapy: an observational study. Am J Hypertens 2012; 25: 195–203.
7. Hasford J, Schroder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein G. Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study. Eur J Clin Pharmacol 2007; 63: 1055–61.
8. Burnier M. Antihypertensive combination treatment: state of the art. Curr Hypertens Rep 2015; 17: 51.
9. Angeli F, Reboldi G, Mazzotta G, Garofoli M, Ramundo E, Poltronieri C, et al. Fixed-dose combination therapy in hypertension: cons. High Blood Press Cardiovasc Prev 2012; 19: 51–4.
10. Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free- and fixed-dose combinations. Curr Med Res Opin 2008; 24: 2597–2607.
11. Akazawa M, Fukuoka K. Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis. BMC Health Serv Res 2013; 13: 124.
12. Clarke PM, Avery AB. Evaluating the costs and benefits of using combination therapies. Med J Aust 2014; 200: 518–20.
13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507–20.
14. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2015; 31: 549–68.
15. Abdul Rahman AR, Reyes EB, Sritara P, Pancholia A, Van Phuoc D, Tomlinson B. Combination therapy in hypertension: an Asia-Pacific consensus viewpoint. Curr Med Res Opin 2015; 31: 865–74.
16. National Heart Foundation of Australia. Guide to management of hypertension 2008 (Updated December 2010) [online]. Available at https://heartfoundation.org.au/images/uploads/publications/HypertensionGuidelines2008to2010Update.pdf (last accessed 20 May 2016).
17. Byrd JB, Zeng C, Tavel HM, Magid DJ, O'Connor PJ, Margolis KL, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J 2011; 162: 340–6.
18. Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001; 14: 286–92.
19. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59: 1124–31.
20. Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61: 309–18.
21. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399–407.
22. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ 2011; 14: 576–83.
23. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 2010; 26: 2065–76.
24. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs. free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 2011; 13: 898–909.
25. Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010; 26: 2877–2887.
26. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28: 1584–90.
27. Tu K, Anderson LN, Butt DA, Quan H, Hemmelgarn BR, Campbell NR, et al. Hypertension Outcome Surveillance Team. Antihypertensive drug prescribing and persistence among new elderly users: implications for persistence improvement interventions. Can J Cardiol 2014; 30: 647–52.
28. Patel BV, Remigio-Baker RA, Thiebaud P, Preblick R, Plauschinat C. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008; 9: 61.
29. Gadzhanova S, Ilomaki J, Roughead EE. Antihypertensive use before and after initiation of fixed-dose combination products in Australia: a retrospective study. Int J Clin Pharmacol 2013; 35: 613–20.
30. Gu Q, Paulose-Ram R, Dillon C, Burt V. Antihypertensive medication use among US adults with hypertension. Circulation 2006; 113: 213–21.
31. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Giudelines 18 and 34 (Internet). London: Royal College of Physicians, 2011.
32. van Wijk BL, Avorn J, Solomon DH, Klungel OH, Heerdink ER, de Boer A, et al. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. J Hypertens 2007; 25: 689–97.
33. Kent ST, Shimbo D, Huang L, Diaz KM, Kilgore ML, Oparil S, et al. Antihypertensive medication classes used among Medicare beneficiaries initiating treatment in 2007–2010. PLoS One 2014; 9: e105888.
34. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2014; 63: 878–85.
35. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.
36. Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006–2010. Med J Aust 2011; 195: 134–7.
37. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011; 123: 1611–21.
38. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 11: CD000011